Needham Maintains Buy on Azenta, Raises Price Target to $78
Needham analyst David Saxon maintains Azenta (NASDAQ:AZTA) with a Buy and raises the price target from $74 to $78.
Nasdaq, S&P 500 Futures Skyrocket After Tamer PPI Data That Confirms Slowing Inflation, Walmart’s Beat-And-Raise Q3
The index futures are solidly higher in premarket trading on Tuesday, as stocks strive to return to winning ways amid lingering hopes of a Fed pause.
Earnings Scheduled For November 14, 2022
Companies Reporting Before The Bell
• Opiant Pharma (NASDAQ:OPNT) is estimated to report quarterly loss at $1.49 per share on revenue of $3.68 million.
Keybanc Maintains Overweight on Azenta, Lowers Price Target to $70
Keybanc analyst Paul Knight maintains Azenta (NASDAQ:AZTA) with a Overweight and lowers the price target from $90 to $70.
